Kura Oncology's partnership with Kyowa Kirin centered on ziftomenib offers long-term benefits, however, commercialization and significant royalties will take time to materialize. Ziftomenib, Kura's ...
Kura Oncology (NASDAQ:KURA) stock slid 7% in post-market trading after the company issued an update on its drug ziftomenib. Kura (NASDAQ:KURA) reported positive Phase 2 data from a ...
Kura Oncology, Inc., a clinical-stage biopharmaceutical company focused on precision cancer treatments, announced its participation in three upcoming investor conferences. Management will engage in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results